Canlyniadau Chwilio - Shanu Modi

Mireinio'r Canlyniadau
  1. 1
    Ganetespib: research and clinical development

    Ganetespib: research and clinical development gan Shanu Modi, Komal Jhaveri

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    HER2 breast cancer therapies: a review

    HER2 breast cancer therapies: a review gan Shanu Modi, Conleth G. Murphy

    Cyhoeddwyd 2009
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Unlocking the potential of antibody–drug conjugates for cancer therapy

    Unlocking the potential of antibody–drug conjugates for cancer therapy gan Joshua Z. Drago, Shanu Modi, Sarat Chandarlapaty

    Cyhoeddwyd 2021
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

    Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions gan Emanuela Ferraro, Joshua Z. Drago, Shanu Modi

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers

    Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers gan Komal Jhaveri, Tony Taldone, Shanu Modi, Gabriela Chiosis

    Cyhoeddwyd 2011
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment

    Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment gan Hardik Patel, Shanu Modi, Gabriela Chiosis, Tony Taldone

    Cyhoeddwyd 2011
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Beyond HER2: Targeting the ErbB receptor family in breast cancer

    Beyond HER2: Targeting the ErbB receptor family in breast cancer gan Joshua Z. Drago, Emanuela Ferraro, Nour Abuhadra, Shanu Modi

    Cyhoeddwyd 2022
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane

    Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane gan Monica Fornier, Shanu Modi, Katherine S. Panageas, Larry Norton, Clifford A. Hudis

    Cyhoeddwyd 2005
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer

    Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer gan Giuseppe Curigliano, Rebecca Dent, H. Earle, Shanu Modi, Paolo Tarantino, Giulia Viale, Sara M. Tolaney

    Cyhoeddwyd 2024
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Chaperome heterogeneity and its implications for cancer study and treatment

    Chaperome heterogeneity and its implications for cancer study and treatment gan Tai Wang, Anna Rodina, Mark Dunphy, Adriana Corben, Shanu Modi, Mónica L. Guzmán, D.T. Gewirth, Gabriela Chiosis

    Cyhoeddwyd 2018
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer

    A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer gan Muralidhar Beeram, Ian E. Krop, Howard A. Burris, Sandhya Girish, Wei Yu, Michael W. Lu, Scott N. Holden, Shanu Modi

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer gan Ian E. Krop, Shanu Modi, Patricia LoRusso, Mark D. Pegram, Ellie Guardino, Betsy Althaus, Dan Lu, Alexander Strasak, Anthony Elias

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer

    Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer gan Azael Freites‐Martínez, Jerry Shapiro, Donald Chan, Monica Fornier, Shanu Modi, Devika Gajria, Stephen W. Dusza, Shari Goldfarb, Mario E. Lacouture

    Cyhoeddwyd 2018
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

    Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies gan Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, Shanu Modi, Aditya Bardia, Sara M. Tolaney, Javier Cortés, Jean‐Charles Soria, Giuseppe Curigliano

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation

    The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation gan T. Jonathan Yang, Monica Morrow, Shanu Modi, Zhigang Zhang, Kate Krause, Chun Siu, Beryl McCormick, Simon N. Powell, Alice Y. Ho

    Cyhoeddwyd 2015
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    A Reversible Case of Advanced Interstitial Lung Disease in a Patient with HER2 Low Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan

    A Reversible Case of Advanced Interstitial Lung Disease in a Patient with HER2 Low Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan gan Felipe Marques da Costa, Milena Tenório Cerezoli, Augusto Kreling Medeiros, Gabriela Machado Novaes, B.R. da Silva, Fernando Cotait Maluf, Shanu Modi

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors

    A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors gan Komal Jhaveri, Kathy D. Miller, Lee S. Rosen, Bryan P. Schneider, Linnea Chap, Alison L. Hannah, Ziyang Zhong, Weining Ma, Clifford A. Hudis, Shanu Modi

    Cyhoeddwyd 2012
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

    A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer gan Shanu Modi, Cristina Saura, Charles Henderson, Nancy U. Lin, Reshma Mahtani, Jill Goddard, Eduard Ródenas‐Alesina, Clifford A. Hudis, Joyce O’Shaughnessy, José Baselga

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies

    Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies gan Shunji Takahashi, Hideaki Bando, Ichiro Kinoshita, Shanu Modi, Junji Tsurutani, Yung‐Jue Bang, Yuta Sato, Shunsuke Nakatani, Caleb Lee, Masahiro Sugihara, Yasuyuki Okuda, Hiroji Iwata

    Cyhoeddwyd 2024
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

    Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer gan Sarat Chandarlapaty, Rita A. Sakr, Dilip D. Giri, Sujata Patil, Adriana Heguy, Monica Morrow, Shanu Modi, Larry Norton, Neal Rosen, Clifford A. Hudis, Tari A. King

    Cyhoeddwyd 2012
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: